Cathepsin S inhibition changes regulatory T-cell activity in regulating bladder cancer and immune cell proliferation and apoptosis. (February 2017)

• Record Type: Journal Article
• Authors: Yan, Xiang; Wu, Chun; Chen, Tao; Santos, Marcela M.; Liu, Cong-Lin; Yang, Chongzhe; Zhang, Lijun; Ren, Jingyuan; Liao, Sha; Guo, Hongqiang; Sukhova, Galina K.; Shi, Guo-Ping
• Is Part Of: Molecular immunology. Volume 82(2017:Feb.)
• Page Start: 66
• Page End: 74
• Publication Date: 2017-02
• Subjects: Treg regulatory T-cell -- CatS cathepsin S -- CatK cathepsin K -- CatL cathepsin L -- PD-L1 programmed death ligand 1 -- PTEN phosphatase and tensin homolog -- TLR7 toll-like receptor-7 -- WT wild-type -- TUNEL terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling -- FBS fetal bovine serum -- PBS phosphate-buffered saline; Regulatory T-cell -- Bladder cancer -- Splenocytes -- Cathepsin S -- Proliferation -- Apoptosis; Immunochemistry -- Periodicals; Molecular biology -- Periodicals; Immunochemistry -- Periodicals; Allergy and Immunology -- Periodicals; Molecular Biology -- Periodicals; Immunochimie -- Périodiques; Biologie moléculaire -- Périodiques; Immunochemistry; Molecular biology; Periodicals; Electronic journals; 571.96
• DOI: 10.1016/j.molimm.2016.12.018
• Languages: English
• ISSNs: 0161-5890

Abstract

Highlights: Cathepsin S inhibitor- or saline-treated Tregs did not affect mouse bladder tumor growth. Tumor mice received inhibitor-treated Tregs had reduced splenic and tumor Treg number and total cell proliferation. Inhibitor-treated Tregs affected the proliferation and apoptosis of tumor cells and splenic lymphocytes differently from saline-treated Treg. Tumor cell conditioned media affected inhibitor-treated Treg activity in regulating lymphocyte proliferation and apoptosis. Abstract: Regulatory T cells (Tregs) are immune suppressive cells, but their roles in tumor growth have been elusive, depending on tumor type or site. Our prior study demonstrated a role of cathepsin S (CatS) in reducing Treg immunosuppressive activity. Therefore, CatS inhibition in Tregs may exacerbate tumor growth. Using mouse bladder carcinoma MB49 cell subcutaneous implant tumor model, we detected no difference in tumor growth, whether mice were given saline- or CatS inhibitor-treated Tregs. However, mice that received inhibitor-treated Tregs had fewer splenic and tumor Tregs, and lower levels of tumor and splenic cell proliferation than mice that received saline-treated Tregs. In vitro, inhibitor-treated Tregs showed lower proliferation and higher apoptosis than saline-treated Tregs when cells were exposed to MB49. In contrast, both types of Tregs showed no difference in proliferation when they were co-cultured with normal splenocytes. Inhibitor-treated Tregs had less apoptosis in splenocytes, but more apoptosis in splenocytes with MB49 conditioned media than saline-treated Tregs. In turn, we detected less proliferation and more apoptosis of MB94 cells after co-culture with inhibitor-treated Tregs, compared with saline-treated Tregs. B220 + B-cell, CD4 + T-cell, and CD8 + T-cell proliferation and apoptosis were also lower in splenocytes co-cultured with inhibitor-treated Tregs than with saline-treated Tregs. Under the same conditions, the addition of cancer cell-conditioned media greatly increased CD8 + T-cell proliferation and reduced CD8 + T-cell apoptosis. These observations suggest that CatS inhibition of Tregs may reduce overall T-cell immunity under normal conditions, but enhance CD8 + T-cell immunity in the presence of cancer cells.